The North America glycomics market is expected to grow from US$ 598.44 million in 2022 to US$ 1,289.32 million by 2028; it is estimated to grow at a CAGR of 13.6% from 2022 to 2028.
As scientists have concentrated their efforts on glycomics, they have started to learn important details about the functions of glycans and glycosylation in the body, including cellular communication, and what these factors might reveal about disease development and diagnostics. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions. For instance, in March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet—a Network of Centers of Excellence centered at the University of Alberta for Glycomics Research—is providing the funds to enhance Canadians' quality of life. In March 2022, researchers from GlycoNet developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Several advancements show that glycomics has the potential to provide rapid and accurate diagnostics methods that transcend diverse clinical indications and complex conditions. Therefore, the use of glycomics in drug development across the region is acting as a key market driver.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America glycomics market. The North America glycomics market is expected to grow at a good CAGR during the forecast period.
North America Glycomics Market Revenue and Forecast to 2028 (US$ Million)
North America Glycomics Market Segmentation
The North America glycomics market is segmented based on product, application, end user, and country. Based on product, the North America glycomics market is segmented into enzymes, instruments, kits, and reagents. The enzymes segment dominated the market in 2022. The enzymes segment is further segmented into glycosidases, glycosyl transferases, sialyltransferases, neuraminidases, and others. The instruments segment is also segmented into mass spectrometers, MALDI-TOF, HPLC, lectin arrays, antibody arrays, and others. Similarly, the kits segment is segmented into glycan release kits, glycan labeling kits, glycan purification kits, and others. Furthermore, the reagents segment is segmented into oligosaccharides, monosaccharides, glycoproteins, and others. Based on application, the North America glycomics market is segmented into drug discovery and development, diagnostics, immunology, cancer, and others. The drug discovery and development segment dominated the market in 2022. Based on end user, the North America glycomics market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations. The pharmaceutical & biotechnology companies segment dominated the market in 2022. Based on country, the North America glycomics market has been categorized into the US, Canada, and Mexico. The US dominated the market in 2022.
Agilent Technologies, Inc.; Bruker Corporation; MERCK KGaA; New England Biolabs; S-BIO (Sumitomo Bakelite Co., Ltd.); Shimadzu Corporation; Takara Bio Inc.; Thermo Fisher Scientific Inc.; and Waters Corporation are among the leading companies in the North America glycomics market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 598.44 Million |
| Market Size by 2028 | US$ 1,289.32 Million |
| CAGR (2022 - 2028) | 13.6% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Glycomics Market is valued at US$ 598.44 Million in 2022, it is projected to reach US$ 1,289.32 Million by 2028.
As per our report North America Glycomics Market, the market size is valued at US$ 598.44 Million in 2022, projecting it to reach US$ 1,289.32 Million by 2028. This translates to a CAGR of approximately 13.6% during the forecast period.
The North America Glycomics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Glycomics Market report:
The North America Glycomics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Glycomics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Glycomics Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)